New Indication for Procrit in Elective Surgeries
February 1st 1997RARITAN, NJ--Procrit (Epoetin alfa) has received marketing clearance by the FDA for use in reducing the need for allogeneic blood transfusions in anemic patients scheduled to undergo elective noncardiac, nonvascular surgery. Patients should be at high risk for perioperative transfusion with significant, anticipated blood loss. Procrit is not indicated for anemic patients who are willing to donate autologous blood.
Clinical Studies of IL-11, New Platelet Growth Factor, Presented
February 1st 1997Recombinant human interleukin-11 (IL-11 [Neumega]) stimulates platelet production and inhibits inflammation in clinical studies in cancer patients, according to research presented at a symposium held last summer in New York City. The potential
PET Shows Promise in Screening for Axillary Node Metastases
February 1st 1997CHICAGO--Positron emission tomography (PET) has excellent potential as a screening test for spotting axillary lymph node metastases in women with newly diagnosed, early-stage breast cancer, thereby sparing many women from unnecessary lymph node dissection, Lee Adler, MD, of Case Western Reserve University, said at the Radiological Society of North America meeting.
Intraoperative Radiation Allows Lumpectomy Patients to Skip Boost
February 1st 1997TOLEDO, Ohio-Researchers at the Medical College of Ohio have treated a series of breast-conservation patients with intraoperative electron beam radiation to the tumor bed, in conjunction with a course of 45 to 50 Gy of external beam radiation.
States Consider Model Managed Care Consumer Protection Bill
February 1st 1997WASHINGTON--State legislators from nine states announced they will introduce the Managed Care Consumer Protection Act when their respective legislatures convene this year. Legislators in others states may also introduce the "model" bill, drafted by a bipartisan group of state legislators. The drafting panel said it sought to avoid piecemeal attempts to resolve conflicts between consumers and managed care plans by drafting a comprehensive, uniform bill.
Pact With NCI Expands Veterans' Access to Trials
February 1st 1997BETHESDA, Md--In a move designed to increase the pool of patients available for clinical trials, the National Cancer Institute has forged an agreement with the Department of Veterans Affairs that will increase the ability of veterans to enroll in phase I, II, and III studies.
Breast Palpation at Time of Breast Implant Excision May Find Cancer
February 1st 1997DALLAS--Breast implant excision or exchange offers a unique cancer screening opportunity in breasts frequently difficult to check manually or radiologically, William Shaw, MD, said at the American Society of Plastic and Reconstructive Surgeons annual meeting.
New Series to Explore Cancer Genetic Issues
February 1st 1997The familial aggregation of cancer has piqued the curiosity of physicians for more than two millennia. Most explanations for this aggregation were based upon environmental hypotheses, such as diet, solar radiation, habit patterns, and cultural practices, as well as occupational exposures. On rare occasions, ancients and now, more frequently, contemporaries have suggested that genetics might provide an important causal explanation for familial cancer.
Viatical Proceeds Tax-Free if Individuals Qualify
February 1st 1997Physicians can expect to see more requests for medical records by companies offering viatical settlements to terminally ill or chronically ill patients who meet certain criteria as certified by their physicians. The viatical industry, which has been marketing its services primarily to AIDS patients through gay publications and networks, is maturing as a result of new federal legislation granting tax-free status to the proceeds and as viatical companies expand their marketing efforts to the population at large.
Expanded Role for Bisphosphonates in Metastatic Breast Cancer
February 1st 1997SAN ANTONIO--Bisphosphon-ates are indicated in patients with established bone metastases from breast cancer or myeloma, to reduce skeletal complications, Alexander H.G. Paterson, MD, said at a minisymposium held in conjunction with the San Antonio Breast Cancer Symposium.
FDA Proposes Selection Process for Patient Reps
February 1st 1997ROCKVILLE, Md--The FDA has proposed a formal process for selecting patient representatives to serve on its cancer-related advisory boards--the Onco-logic Drugs Advisory Committee, the Biological Response Modifiers Advisory Committee, and the Medical Imaging Drugs Advisory Committee.
New Website Gateway to Vast Array of Cancer Resources
February 1st 1997HUNTINGTON, NY--Imagine a website designed exclusively for cancer professionals. It would, of course, offer free access to Medline via a state-of-the-art search tool, as well as access to the National Cancer Institute's PDQ database and CancerLit.
The Crisis of Cancer: Psychological Impact on Family Caregivers
February 1st 1997Drs. Blanchard, Albrecht, and Ruckdeschel provide a whirlwind tour of research on families and cancer. The article has an ambitious mission. It attempts to establish how cancer affects families, through a review of studies that assess the psychological
Postmastectomy Radiation: Then and Now
February 1st 1997Postmastectomy radiotherapy has been used since the early part of the 20th century in an effort to decrease local recurrences and potentially improve survival. It clearly reduces the rate of local chest-wall failure following mastectomy, increases relapse-
The Crisis of Cancer: Psychological Impact on Family Caregivers
February 1st 1997Blanchard et al provide an excellent review of the literature on the psychosocial adjustment of caregivers of the cancer patient. The importance of caregiver function and adaptation to the clinical status of the cancer patient is generally conceded, but the
New Board to Deal With Cancer Policy Issues
January 1st 1997WASHINGTON--A new player has entered the cancer policy arena. At the instigation of NCI director Richard D. Klausner, MD, the National Research Council has established the National Cancer Policy Board to aid the NCI in dealing with policy matters and strategic planning issues outside of cancer research.
Pressures of Managed Care Spur Interest in Clinical Guidelines
January 1st 1997Clinical practice guidelines have been a subject of increasing interest for the past several years, and, recently, they have been developed for oncology. In March, 1996, the National Comprehensive Cancer Network (NCCN), a coalition of 15 major US cancer centers, presented the first version of their practice guidelines in oncology. These guidelines covered most of the major cancer sites.
Baltimore Will Head New Effort To Develop a Vaccine for HIV
January 1st 1997BETHESDA, Md--Nobel laureate David Baltimore, PhD, will lead a National Institutes of Health effort to revive the flagging search for an effective HIV vaccine. NIH Director Harold Varmus, MD, named Dr. Baltimore to head a committee that will search for new ideas and new approaches to a research endeavor that has failed to yield a vaccine after a decade of intense work.
Study Designates Protein As a Selective Marker For Metastatic Colorectal Tumors
January 1st 1997Researchers from Thomas Jefferson University have discovered that the protein guanylyl cyclase C (GCC) is expressed in humans solely in the intestines, including the colon and rectum, making it a selective marker for colorectal tumors that
AIDS Center Director Offers Advice on Selecting a Physician
January 1st 1997NEW YORK--When selecting a physician, the most important question an HIV patient can ask is, How many HIV/AIDS patients have you treated? Ramon A. Gabriel Torres, MD, medical director, AIDS Center, St. Vincent's Hospital, NY, said at a teleconference sponsored by Cancer Care Inc. and the Gay Men's Health Crisis.
Goals of Planned National Pain Research Consortium Outlined
January 1st 1997WASHINGTON--An announcement by NIH director Harold E. Varmus, MD, of a plan to form a national pain research consortium came as a complete, but pleasant surprise to the American Pain Society, Martin Grabois, MD, president of the Society, said in an interview with Oncology News International.
New Evidence Supports Screening in Younger Women
January 1st 1997CHICAGO--Medical groups that advocate routine screening mammogra-phy for women between the ages of 40 and 49 have new ammunition to challenge the NCI's controversial 1993 decision to raise the suggested age for beginning mammography screening to 50 years.
Fludarabine Effective as First-Line CLL Therapy
January 1st 1997ORLANDO--Fludarabine (Flu-dara) improves response, duration of response, and progression-free survival over standard therapy in previously untreated patients with active B-cell chronic lymphocytic leukemia (CLL), and it should be included in the list of drugs for first-line treatment of this disease, Kanti R. Rai, MD, said at the 38th Annual Meeting of the American Society of Hematology (ASH).